Dr. Matthew (Matt) Gevaert is the CEO of KIYATEC Inc., a company on a mission to change the future of cancer care by accurately predicting patient-specific response and non-response to cancer drugs before treatment begins. KIYATEC utilizes a patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies in its CLIA and research laboratories with an approach that has been validated through engagements with leading cancer hospitals, multiple top 10 pharmaceutical companies and the NCI.
Before co-founding KIYATEC Gevaert led the commercialization of Clemson University’s biomedical and biotechnology intellectual property portfolio and has previous employment with Merck, 3M and Dow Chemical. Gevaert holds a bachelor’s degree in Chemistry from the University of Waterloo (Canada) and a doctorate in Bioengineering from Clemson University, and has additional experience at the University of Notre Dame and at the University of Sussex (UK). He maintains current appointments as adjunct professor in the Clemson University Department of Bioengineering and as a lecturer in the Clemson MBA in Entrepreneurship & Innovation.